Papers matching “paroxysmal nocturnal hemoglobinuria” in Complement system in diseases 94
Not finding it? Sign in to also search OpenAlex live.
-
Efficacy, Safety, and Quality of Life of Pegcetacoplan in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria Treated within the Phase 3 PEGASUS Trial2024 Acta Haematologica article Immunology and Microbiology Complement system in diseases Open access
Hisakazu Nishimori, Hideyuki Nakazawa, Shinobu Tamura, Toshiki Uchida, Kensuke Usuki, Johan Szamosi, +3 more
4citations -
COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria
Régis Peffault de Latour, Simona Sica, Julia G. Ramos, Jules Hernández‐Sánchez, Jin Seok Kim, Anna Kiialainen, +11 more
3citations -
P781: EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH AND WITHOUT BONE MARROW FAILURE: A MOVE TOWARDS INDIVIDUALIZED PATIENT TREATMENT
Jeff Szer, Jens Panse, Austin Gladston Kulasekararaj, Monika Oliver, Bruno Fattizzo, Jun‐ichi Nishimura, +3 more
1citations -
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria2021 New England Journal of Medicine article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent
Peter Hillmen, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +11 more
407citations -
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria2024 American Journal of Hematology article Immunology and Microbiology Complement system in diseases Open access
Phillip Scheinberg, Diego V. Clé, Jin Seok Kim, Erfan Nur, Mustafa Nuri Yenerel, Wilma Barcellini, +15 more
52citations -
The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target2022 Immunological Reviews review Immunology and Microbiology Complement system in diseases Open access
Antonio Maria Risitano, Camilla Frieri, Eleonora Urciuoli, Luana Marano
52citations -
One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab2020 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access
Austin Gladston Kulasekararaj, Anita Hill, Saskia M. C. Langemeijer, Richard A. Wells, Fernando Ataúlfo González Fernández, Anna Gayà, +12 more
36citations -
Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
Régis Peffault de Latour, Alexander Roeth, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yasutaka Ueda, Carlos M. de Castro, +15 more
23citations -
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study2024 Advances in Therapy article Immunology and Microbiology Complement system in diseases Open access
Christopher Jordan Patriquin, Andrija D. Bogdanovic, Morag Griffin, Richard J. Kelly, Jaroslaw Pawel Maciejewski, Brian Patrick Mulherin, +9 more
20citations -
Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case–control study in the International PNH Registry2023 Annals of Hematology article Immunology and Microbiology Complement system in diseases Open access
Britta Höchsmann, Régis Peffault de Latour, Alexander Röth, Timothy Devos, Christopher Jordan Patriquin, Wen‐Chien Chou, +4 more
19citations -
Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors2023 Clinical Pharmacology & Therapeutics article Immunology and Microbiology Complement system in diseases Open access
Jun‐ichi Nishimura, Antoine Soubret, Noriko Arase, Simon Buatois, Masaki Hotta, Jean‐Eric Charoin, +23 more
10citations -
S183: PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Phillip Scheinberg, Diego V. Clé, Valentina Giai, Marek Hus, Jin Seok Kim, Cristina Barrenetxea Lekue, +11 more
5citations -
Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors
Jens Panse, Nicolas Daguindau, Sonia Okuyama, Régis Peffault de Latour, Philippe Schafhausen, Nicole Straetmans, +3 more
3citations -
An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial
Jun‐ichi Nishimura, Antoine Soubret, Simon Buatois, Jean‐Eric Charoin, Sasha Sreckovic, Christoph Marcus Bucher, +21 more
3citations -
P774: SUBSTANTIAL INCREASES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE WITH ORAL IPTACOPAN MONOTHERAPY CONFIRMS CONTROL OF HEMOLYSIS IN COMPLEMENT INHIBITOR-NAÏVE PNH PATIENTS
Régis Peffault de Latour, Bing Han, Jaroslaw Pawel Maciejewski, Yutaka Ueda, Rong Fu, Li Zhang, +15 more
3citations